German study reveals Real-World use of PRRT for neuroendocrine tumors
NCT ID NCT07653126
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 117 people with gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) who received a type of radiation therapy called PRRT in German clinics. Researchers collected information on patient characteristics, treatment timing, and how PRRT was given in everyday practice. The goal was to better understand real-world treatment patterns, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE/DOTATOC or Lutathera®
- What this could lead to
- If successful, this study could help doctors better understand how PRRT is used in real-world settings, potentially improving treatment guidelines for neuroendocrine tumors.
- What could go wrong
- This is a retrospective observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Essen, Germany
-
Novartis Investigative Site
Heidelberg, Germany
-
Novartis Investigative Site
München, Germany
-
Novartis Investigative Site
Rostock, Germany
-
Novartis Investigative Site
Stuttgart, Germany
-
Novartis Investigative Site
Tübingen, Germany
-
Novartis Investigative Site
Würzburg, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.